Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC

Prof Ferdinandos Skoulidis speaks to ecancer about the primary analysis of the phase III Krascendo 1 trial, which compared divarasib, a next-generation KRAS G12C inhibitor, with sotorasib or adagrasib in patients with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).

Among 338 patients, divarasib significantly improved progression-free survival, extending median progression-free survival from 5.7 to 9.8 months, and overall survival, increasing median overall survival from 12.0 to 17.7 months.

The objective response rate was also higher with divarasib, at 58.4% compared with 32.3% with sotorasib or adagrasib.

Divarasib demonstrated a manageable safety profile. Grade 3–4 treatment-related adverse events occurred in 24.6% of patients receiving divarasib compared with 34.5% in the control group.

Treatment discontinuations due to treatment-related adverse events were also less frequent with divarasib (4.8% vs 11.7%).

Prof Skoulidis says that these findings demonstrate significant improvements in progression-free and overall survival with divarasib compared with currently available KRAS G12C inhibitors, supporting its potential as a new standard of care for previously treated advanced KRAS G12C-mutated NSCLC.